I'm replying to myself here, but....
Study 305:
This is OnCARlytics in combo with Blinatumomab, made by Amgen and marketed as "Blincyto."
At present, Blincyto is just a second line treatment for a particular and relatively uncommon type of leukaemia, but Blincyto is an FDA approved drug. I doubt it's a big seller, but Amgen is huge. Big Pharma.
And now they discover that their already approved niche product - Blincyto - when used in combination with OnCARlytics - shows "specific tumor cell killing in vitro and robust anti-tumor efficacy" against "in vivo human triple-negative breast cancer". ie. one of the hardest to treat types of cancer.
I think Amgen will be beyond interested in this result.
Cheers
Dave
Media Thread, page-7368
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.6¢ |
Change
0.001(2.22%) |
Mkt cap ! $342.1M | |||
| Open | High | Low | Value | Volume |
| 4.5¢ | 4.7¢ | 4.5¢ | $906.2K | 19.67M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 9543864 | 4.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.6¢ | 1266571 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |